FibroGen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 486
- Market Cap
- $38.6M
- Website
- http://www.fibrogen.com
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 356
- Registration Number
- NCT03955146
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 284
- Registration Number
- NCT03941093
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 43
- Registration Number
- NCT03303066
- Locations
- 🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳Zhuzhou Central Hospital, Zhuzhou, Guangdong, China
🇨🇳Second hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 184
- Registration Number
- NCT03263091
- Locations
- 🇺🇸
Investgational site, Atlanta, Georgia, United States
🇺🇸Investiational Site, Weston, Florida, United States
🇮🇱Investigational site, Tel HaShomer, Israel
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 154
- Registration Number
- NCT02652819
- Locations
- 🇨🇳
Ningbo No.2 Hospital, Ningbo, Zhejiang, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳301 Hospital, Beijing, Beijing, China
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 305
- Registration Number
- NCT02652806
- Locations
- 🇨🇳
The First Affiliated hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 21
- Registration Number
- NCT02606136
- Locations
- 🇺🇸
University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Rare Disease Research, Atlanta, Georgia, United States
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 741
- Registration Number
- NCT02273726
- Locations
- 🇵🇷
Research Center, San Juan, Puerto Rico
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 37
- Registration Number
- NCT02210559
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Virginia Mason Medical Center - Benaroya Research Institute, Seattle, Washington, United States
🇺🇸Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 1043
- Registration Number
- NCT02052310
- Locations
- 🇧🇬
Invesigational Site, Stara Zagora, Bulgaria
🇷🇺Investigational site, St. Petersburg, Russian Federation
🇺🇸Meridian, Meridian, Idaho, United States